Mir-218-5p from Extracellular Vesicles of Endometrium in Patients with Recurrent Implantation Failure Impairs Pre-Implantation Embryo Development
Quick Facts
- Publication title: Mir-218-5p from Extracellular Vesicles of Endometrium in Patients with Recurrent Implantation Failure Impairs Pre-Implantation Embryo Development
- Journal: Int J Nanomedicine
- Year: 2025
- DOI: 10.2147/IJN.S508491
- PMID/PMCID: 40331233; PMC12052006
Research overview
In this study, we aimed to investigate the effectiveness of miR-218-5p as a molecular factor in RIF-EVs. This research provides a novel and non-invasive insight into potential therapeutic strategies for RIF.
Key findings
Essential transcription factors for TE and ICM, such as Cdx2, Yap1, Sox2, Nanog, Tead4, were reduced at the mRNA level in the miR-218-5p treated morula.
001) and disruption of co-localization of Yap1 and Cdx2.
Study design
The percentage of blastocyst development and hatching rates, embryo morphology, and the total cell number were measured.
RNA-sequencing was used to analyze transcriptional changes in embryos post miR-218-5p agomir treatment.
The abnormal segregation genes of trophectoderm (TE) and inner cell mass (ICM) were visualized via qRT-PCR and immunofluorescence staining.
Echo Biotech Role
Echo Biotech contributed cargo loading; the study also used or cited ExoLoad®.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Small RNA / Cargo Loading, Research Reagent / Product Supply
Related products or reagents: ExoLoad® Nucleic Acid Loading Kit
References
Original publication: Mir-218-5p from Extracellular Vesicles of Endometrium in Patients with Recurrent Implantation Failure Impairs Pre-Implantation Embryo Development International journal of nanomedicine. 2025. DOI: 10.2147/IJN.S508491. PMID/PMCID: 40331233; PMC12052006.